DBV Technologies (DBVT) Non-Current Assets (2015 - 2026)
DBV Technologies (DBVT) posted quarterly Non-Current Assets of $21.3 million for Q2 2026, down 4.0% year-on-year from $22.2 million in Q2 2025, and up 8.12% on a QoQ basis from $19.7 million in Q1 2026.
DBV Technologies (DBVT) Non-Current Assets (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Non-Current Assets for 12 consecutive years, with $21.3 million the latest figure, recorded in Q2 2026.
- Quarterly Non-Current Assets fell 4.0% year-over-year to $21.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $21.3 million (down 4.0% YoY) and the FY2025 annual result came in at $20.8 million, down 2.21% from the prior year.
- Non-Current Assets advanced to $21.3 million in Q2 2026 per DBVT's latest filing, from $19.7 million in the prior quarter.
- Over the last five years, Non-Current Assets for DBVT reached as high as $27.1 million in Q1 2022 and fell as low as $19.7 million in Q1 2026.
- A 5-year average of $22.8 million and a median of $22.3 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets slumped 63.11% — and 2024, when it advanced 18.44%.
- Year by year, Non-Current Assets stood at $23.4 million in 2022, then increased by 2.67% to $24.1 million in 2023, then slipped by 11.63% to $21.3 million in 2024, then fell by 2.21% to $20.8 million in 2025, then climbed by 2.4% to $21.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $21.3 million, $19.7 million, and $20.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 21.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.30 Mn |
| Mar 31, 2026 | 19.70 Mn |
| Dec 31, 2025 | 20.80 Mn |
| Sep 30, 2025 | 21.61 Mn |
| Jun 30, 2025 | 22.19 Mn |
| Mar 31, 2025 | 21.41 Mn |
| Dec 31, 2024 | 21.27 Mn |
| Sep 30, 2024 | 24.30 Mn |
| Jun 30, 2024 | 24.23 Mn |
| Mar 31, 2024 | 26.33 Mn |
| Dec 31, 2023 | 24.07 Mn |
| Sep 30, 2023 | 20.51 Mn |
| Jun 30, 2023 | 21.98 Mn |
| Mar 31, 2023 | 22.69 Mn |
| Dec 31, 2022 | 23.44 Mn |
| Sep 30, 2022 | 22.42 Mn |
| Jun 30, 2022 | 25.03 Mn |
| Mar 31, 2022 | 27.14 Mn |
| Dec 31, 2021 | 32.34 Mn |
| Sep 30, 2021 | 60.79 Mn |